Skip to main content

Table 7 BMD results for nano-CeO2 PMN influx in vivo and cytokine endpoints in vitro

From: Establishing relationships between particle-induced in vitro and in vivo inflammation endpoints to better extrapolate between in vitro markers and in vivo fibrosis

Particle

Study

Model

Endpoint

COV in controls (%)

BMR (%)

BMDL (cm2/cm2)

BMDU (cm2/cm2)

Magnitude change [log10(BMDU) – log10(BMDL)]

Nano-CeO2

in vivo IVIVE

Rat inhalation

PMN

n.d.—99.08

100

0.117

0.287

0.390

Nano-CeO2

Cappellini et al. [57]

A549 + dTHP-1 (sub.)

IL-1β

42.23

20

0.593

7.4

1.096

Nano-CeO2

Cappellini et al. [57]

A549 + dTHP-1 (sub.)

IL-6

12.23

20

2.44

7.92

0.511

Nano-CeO2 (23)

Kim et al. [58]

MH-S

IL-6

43.30

20

0.00651

0.0833

1.107

Nano-CeO2 (88)

Kim et al. [58]

MH-S

IL-6

43.30

20

0.00335

0.0322

0.983

  1. The in vitro endpoints included are those that show dose-dependent increases following exposure to nano-CeO2. BMDL/U20 are given for the in vitro endpoints and BMDL/U100 values are provided for in vivo PMN influx